Jonathan Ledermann

27PUBLICATIONS
88CO-AUTHORS
Molecular targetsCancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Social epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Oct 02, 2026
Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD?

|Jun 18, 2025
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.

Uma A Mukherjee, Rowan E Miller, Jonathan A Ledermann

|Nov 09, 2024
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London.

Karim H El-Shakankery, Joanna Kefas, Kieran Palmer

|Oct 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

Lucy Haggstrom, Yeh Chen Lee, Clare Scott

|Sep 04, 2024
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population☆.

Eve Merry, Ronas Taner Kesmez, Tamara Yu

|May 17, 2024
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).

Agnieszka Michael, William Wilson, Sunny Sunshine

Pageof 5

Frequent Collaborators

3 joint publications

Christina Fotopoulou

3 joint publications

Michael L Friedlander

3 joint publications

Osnat Elyashiv

3 joint publications

Robert L Coleman